Alteogen and Biogen Partner for The Development of Subcutaneous Biologics with Hybrozyme™ Technology Alteogen Inc. has partnered with Biogen to license its cutting-edge Hybrozyme™ technology for developing two subcutaneous biologics. This collaboration is set to revolutionize patient care, providing innovative therapies.

Alteogen and Biogen Partner for The Development of Subcutaneous Biologics with Hybrozyme™ Technology #South_Korea #Biogen #Daejeon #Alteogen #Hybrozyme

Alteogen Partners with Tesaro for Innovative Dostarlimab Formulation Development Alteogen has signed an exclusive deal with Tesaro to develop a subcutaneous formulation of Dostarlimab using cutting-edge Hybrozyme™ technology. The collaboration promises significant advancements in oncology.

Alteogen Partners with Tesaro for Innovative Dostarlimab Formulation Development #South_Korea #Daejeon #Alteogen #Dostarlimab #Hyaluronidase

K-Bio’s Innovative Technologies Captivate Global Pharma South Korea’s biotechnology industry is on the verge of opening a new chapter — the era of 20 trillion won in annual technology exports for the first time in h

"South Korea is no longer a latecomer, but a global innovation partner."
#bio #pharma #bigpharma #ablbio #alteogen #biotechnology #export #it #itchosun #chosun #SouthKorea #Korea #NewsUpdate

Alteogen's Novel Biosimilar EYLUXVI® Secures European Commission Approval Alteogen Inc. celebrates EC approval for EYLUXVI®, expanding its biosimilar portfolio. This new formulation targets critical ophthalmic conditions and enhances availability.

Alteogen's Novel Biosimilar EYLUXVI® Secures European Commission Approval #South_Korea #Daejeon #Biosimilar #EYLUXVI #Alteogen

Korea bio Companies Dreaming of Leaving KOSDAQ for KOSPI Korea’s leading bio stocks, Alteogen and HLB, are both moving to transfer their listings to KOSPI, stirring up the capital market. As the “escape from KOSDAQ”

Alteogen and HLB Push for KOSPI Transfer Listing
#bio #alteogen #hlb #kospi #kosdaq #invest #investment #ipo #stock #it #itchosun #chosun #SouthKorea #Korea #NewsUpdate

Alteogen's Aflibercept Biosimilar EYLUXVI® Receives Positive CHMP Opinion Alteogen's EYLUXVI®, an aflibercept biosimilar, receives a positive opinion from CHMP, paving the way for improved treatment of age-related macular degeneration.

Alteogen's Aflibercept Biosimilar EYLUXVI® Receives Positive CHMP Opinion #South_Korea #Daejeon #Aflibercept #EYLUXVI #Alteogen